These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28941882)

  • 1. Investigation of an algorithm for anti HCV EIA reactivity in blood donor screening in Turkey in the absence of nucleic acid amplification screening.
    Karakoc AE; Berkem R; Irmak H; Demiroz AP; Yenicesu I; Ertugrul N; Arslan Ö; Kemahli S; Yilmaz S; Ozcebe O; Kara A; Ozet G; Acikgoz ZC; Acikgoz T
    Transfus Apher Sci; 2017 Oct; 56(5):732-737. PubMed ID: 28941882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests.
    Hyland C; Seed CR; Kiely P; Parker S; Cowley N; Bolton W
    Vox Sang; 2003 Jul; 85(1):1-8. PubMed ID: 12823724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms.
    Kleinman SH; Stramer SL; Brodsky JP; Caglioti S; Busch MP
    Transfusion; 2006 May; 46(5):695-702. PubMed ID: 16686836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of the signal-to-cutoff ratios of anti-hepatitis C virus enzyme immunoassays in screening of Chinese blood donors.
    Ren FR; Lv QS; Zhuang H; Li JJ; Gong XY; Gao GJ; Liu CL; Wang JX; Yao FZ; Zheng YR; Zhu FM; Tiemuer MH; Bai XH; Shan H
    Transfusion; 2005 Nov; 45(11):1816-22. PubMed ID: 16271110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the safety of blood transfusion by using a combination of two screening assays for hepatitis C virus.
    Zhang K; Wang L; Sun Y; Zhang R; Lin G; Xie J; Li J
    Transfus Med; 2014 Oct; 24(5):297-304. PubMed ID: 25262976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hepatitis C virus seroconversion in a Scottish blood donor: HCV antigen is not comparable with HCV nucleic acid amplification technology screening.
    Dow BC; Munro H; Buchanan I; Ferguson K; Davidson F; Lycett C; Jarvis M; Cleland A; Petrik J; Lumley S; MacLean A
    Vox Sang; 2004 Jan; 86(1):15-20. PubMed ID: 14984555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-Chinese blood center study testing serologic-negative donor samples for hepatitis C virus and human immunodeficiency virus with nucleic acid testing.
    Shan H; Ren FR; Zhao HY; Zhang YZ; Wen GX; Yao FZ; Gao GJ; Yan LX; Jiang CF; Bai XH; Tiemuer MH; Tu YQ; Zhu FM; Zheng YR; Cui L; Liu CL; Gong XY; Lv QS; Zheng P; Ziermann R; Ness P; Wang JX
    Transfusion; 2007 Nov; 47(11):2011-6. PubMed ID: 17958529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R; Lelie N; Busch M; Kleinman S;
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of low cost peptide-based anti-hepatitis C virus screening and confirmatory assays: comparison with commercially available tests.
    Palacios A; Taylor L; Haue L; Luftig RB; Visoná KA
    J Med Virol; 1999 Jul; 58(3):221-6. PubMed ID: 10447416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening.
    Tobler LH; Stramer SL; Lee SR; Masecar BL; Peterson JE; Davis EA; Andrews WE; Brodsky JP; Kleinman SH; Phelps BH; Busch MP
    Transfusion; 2003 Oct; 43(10):1452-9. PubMed ID: 14507279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios.
    El Ekiaby M; Moftah F; Goubran H; van Drimmelen H; LaPerche S; Kleinman S; Busch M; Lelie N
    Transfusion; 2015 Jun; 55(6):1186-94. PubMed ID: 25766141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study on screening blood donors with individual-donation nucleic acid testing in China.
    Dong J; Wu Y; Zhu H; Li G; Lv M; Wu D; Li X; Zhu F; Lv H
    Blood Transfus; 2014 Apr; 12(2):172-9. PubMed ID: 24333061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial follow-up of repeat voluntary blood donors reactive for anti-HCV ELISA.
    Choudhury N; Tulsiani S; Desai P; Shah R; Mathur A; Harimoorthy V
    Asian J Transfus Sci; 2011 Jan; 5(1):26-31. PubMed ID: 21572711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation between signal/cutoff ratios of anti-HCV enzyme immunoassay (EIA) and their true positivity in blood donors].
    Ren FR; Gong XY; Li JJ; Lü QS; Liu CL; Zhuang H; Shan H; Wang JX
    Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):255-8. PubMed ID: 15850510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of repeat testing in Turkish blood donors screened with HBV, HCV and HIV immunoassays and the importance of S/CO ratios in the interpretation of HCV/HIV screening test results and as a determinant for further confirmatory testing.
    Acar A; Kemahli S; Altunay H; Kosan E; Oncul O; Gorenek L; Cavuslu S
    Transfus Med; 2010 Jun; 20(3):152-9. PubMed ID: 20059750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of nucleic acid amplification test on screening of blood donors in Northern Pakistan.
    Niazi SK; Bhatti FA; Salamat N; Ghani E; Tayyab M
    Transfusion; 2015 Jul; 55(7):1803-11. PubMed ID: 25648663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients.
    Macedo de Oliveira A; White KL; Beecham BD; Leschinsky DP; Foley BP; Dockter J; Giachetti C; Safranek TJ
    J Clin Virol; 2006 Jan; 35(1):21-5. PubMed ID: 15921955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of second- and third-generation RIBAs for confirmation of third-generation HCV EIA-reactive blood donations. Retrovirus Epidemiology Donor Study.
    Tobler LH; Lee SR; Stramer SL; Peterson J; Kochesky R; Watanabe K; Quan S; Polito A; Busch MP
    Transfusion; 2000 Aug; 40(8):917-23. PubMed ID: 10960517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of nucleic acid testing in cadaver organ donor screening: detection of hepatitis C virus RNA in seropositive and seronegative donors.
    Aswad S; Khan NS; Comanor L; Chinchilla C; Corado L; Mone T; Mendez R; Mendez R
    J Viral Hepat; 2005 Nov; 12(6):627-34. PubMed ID: 16255764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.